Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Amicus Therapeutics

NASDAQ FOLD
$9.66 0.0000 0.0000%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 15 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

2.93B
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
3.08B
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
1.18
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
302.90M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-31.92 %

Upcoming events Amicus Therapeutics

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Amicus Therapeutics

Stock analysis Amicus Therapeutics

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-19.90 28.42
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.
18.27 4.33
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-58.60 9.95
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
-2.84 0.65
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-112.53 7.67

Price change Amicus Therapeutics per year

8.60$ 25.39$
Min Max

Summary analysis Amicus Therapeutics

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Amicus Therapeutics

Revenue and net income Amicus Therapeutics

All parameters

Stock news Amicus Therapeutics

All news
28 September 2023 в 18:05

Amicus Therapeutics Gets FDA Approval for Pombiliti + Opfolda

28 September 2023 в 18:05

Amicus Therapeutics Gets FDA Approval for Pombiliti + Opfolda

28 October 2022 в 23:30

Amicus Therapeutics Shares Fall 7.4% After Hours As FDA Delays Filing for AT-GAA Therapy

28 October 2022 в 23:25

Amicus Therapeutics Shares Fall 7.4% After Hours As FDA Delays Filing for AT-GAA Therapy

30 September 2021 в 14:45

Amicus Therapeutics upgraded to overweight from neutral at JPMorgan, price target $16

29 September 2021 в 14:05

Amicus Therapeutics to Combine Gene-Therapy Unit With SPAC ARYA IV >FOLD

29 September 2021 в 14:05

Amicus Therapeutics to Combine Gene-Therapy Unit With SPAC ARYA IV >FOLD

About company Amicus Therapeutics

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; gene therapies for Fabry and Pompe diseases, as well as for various types of Batten diseases; enzyme replacement therapies for Pompe diseases; and CDKL5 deficiency disorder product candidates. The company also has additional gene therapies in active preclinical development, including gene therapies for mucopolysaccharidosis type IIIB, as well as a next generation program in mucopolysaccharidosis type IIIA. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Address:
3675 Market Street, Philadelphia, PA, United States, 19104
Company name: Amicus Therapeutics
Issuer ticker: FOLD
ISIN: US03152W1099
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2007-05-31
Sector: Healthcare
Industry: Biotechnology
Site: https://amicusrx.com

On which stock exchange are Amicus Therapeutics (FOLD) stocks traded?

Amicus Therapeutics (FOLD) stocks are traded on NASDAQ.

What is the ticker of Amicus Therapeutics stocks (FOLD)?

The stock ticker of Amicus Therapeutics’s stocks or in other words, the code is FOLD. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Amicus Therapeutics (FOLD) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Amicus Therapeutics (FOLD) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are Amicus Therapeutics (FOLD) stocks traded?

Amicus Therapeutics (FOLD) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Amicus Therapeutics (FOLD) stocks today?

The current price of Amicus Therapeutics stocks on 17.05.2024 is 9.66 dollars. per share.

What is the dynamics of Amicus Therapeutics (FOLD) stocks from the beginning of the year?

Amicus Therapeutics (FOLD) quotes have increased by -32.16% from the beginning of the year up to 9.66 dollars. per 1 stocks.

How much did Amicus Therapeutics (FOLD) stocks increase in мае 2024?

This month Amicus Therapeutics (FOLD) quotes have increased by -7.38% to 9.66 dollars. per share.

How much are Amicus Therapeutics (FOLD) stocks worth?

Today, on October, 17.05.2024 Amicus Therapeutics’s (FOLD) stocks cost 9.66 dollars..

What is the market capitalization of Amicus Therapeutics (FOLD)?

Capitalization is the market value of Amicus Therapeutics (FOLD) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 17.05.2024, the market capitalization of Amicus Therapeutics (FOLD) is estimated at about 2926043067 dollars.